Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The...
-
Upload
curtis-moore -
Category
Documents
-
view
215 -
download
2
Transcript of Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The...
![Page 1: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/1.jpg)
Introduction to PharmacoeconomicsSeptember 15 -16, 2009
Karen L. Rascati, PhD, ProfessorThe University of Texas College of Pharmacy
Austin, Texas, USA
The Universidade Federal do Rio Grande do Sul (UFRGS) and the Programa of
Pós-graduação em Economia (PPGE/UFRGS)
![Page 2: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/2.jpg)
Outline
Day 1Part I - What is pharmacoeconomicsPart II – Types of pharmacoeconomic studiesPart III – Costs/OutcomesPart IV – Evaluating StudiesPart V – Evaluation Example 1
![Page 3: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/3.jpg)
Outline
Day 2Part VI – Decision AnalysisPart VII – Markov ModelingPart VIII – Evaluation Example 2Part IX – Future Issues
![Page 4: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/4.jpg)
Part I
What is Pharmacoeconomics?
![Page 5: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/5.jpg)
Definition Pharmacoeconomics “identifies,
measures, and compares costs and consequences of pharmacy products and services”
Some consider it a sub-set of health technology assessment (HTA)
![Page 6: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/6.jpg)
Pharmacoeconomic Equation
COSTS RX OUTCOMES
![Page 7: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/7.jpg)
How much is spent on health care per year as a percent of GDP?In OECD countries?
![Page 8: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/8.jpg)
Health Expenditure as a Share of GDP, 2006
15.3
11.3
11.1
10.6
10.4
10.2
10.1
10.0
9.5 9.3 9.3 9.2 9.1 9.1 9.0 8.8 8.7 8.4 8.4 8.3 8.2 8.2
7.5 7.3 7.1 6.8 6.6 6.4 6.2 5.7
8.9
0
4
8
12
16
Unite
d Stat
es
Switz
erlan
d
Fran
ce
Germ
any
Belgi
um (1
)
Portu
gal
Austr
ia
Cana
da
Denm
ark (
1)
Neth
erlan
ds (2
)
New
Zeala
nd
Swed
en
Gree
ce
Icelan
d Italy
OECD
Austr
alia (
3)
Norw
ay
Spain
Unite
d King
dom
Hung
ary
Finlan
d
Japan
(4)
Irelan
d
Luxe
mbou
rg
Slova
k Rep
ublic
(4)
Czec
h Rep
ublic
Mex
ico
Kore
a
Polan
d
Turk
ey (4
)
% of GDP
Public
Private
(1) Public and private components are current expenditure,i.e. investments are not separated. (2) Current expenditure.(3) Data refer to 2005/06. (4) Data refer to 2005.
![Page 9: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/9.jpg)
Brazil?
![Page 10: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/10.jpg)
Brazil
About 8% GDP on healthcare SUS = tax funded system About half is public spending and half is
private spending (for about 20-30% of population) = much more spent per person if using private insurance
![Page 11: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/11.jpg)
What is the average lifespan for various OECD countries?
![Page 12: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/12.jpg)
![Page 13: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/13.jpg)
Brazil?
![Page 14: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/14.jpg)
Brazil
Life expectancy is about 72 years
![Page 15: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/15.jpg)
Why is Pharmacoeconomics important? Pharmacoeconomics helps assess if
scarce health care resources are being spent wisely on pharmacy products and services.
![Page 16: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/16.jpg)
Part II -Types of Pharmacoeconomic Studies Cost-minimization analysis (CMA) Cost-benefit analysis (CBA) Cost-effectiveness analysis (CEA) Cost-utility analysis (CUA)
COSTS RX OUTCOMES
More than one type may be included in a study (e.g. CEA and CUA)
![Page 17: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/17.jpg)
Types of Pharmacoeconomic StudiesCost-Minimization
Analysis (CMA)
Costs = Monetary units
Outcomes = The same
Cost-Effectiveness Analysis (CEA)
Costs = Monetary units
Outcomes = Natural/clinical units
Cost-Utility
Analysis (CUA)
Costs = Monetary units
Outcomes = Adjusted by quality/utility (e.g., QALY, DALY)
Cost-Benefit Analysis (CBA)
Costs = Monetary units
Outcomes = Monetary units
![Page 18: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/18.jpg)
Other ‘Cost’ Studies
Cost-consequence analysis (CCA)Lists costs and various outcomes presented
but no calculations or comparisons made
Cost-of-illness (COI)Estimate of total economic burden
(prevention, treatment, losses in productivity) of a particular condition or disease on society
![Page 19: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/19.jpg)
Part III – COSTS/OUTCOMES Cost analysis :To identify resources
used or consumed in the production of a good or service and assign monetary values to these resources.
COSTS RX OUTCOMES
![Page 20: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/20.jpg)
Part III – COSTS/OUTCOMES PERSPECTIVE = Whose Costs?
Payer (third-party private/public and/or patient)
Provider/ InstitutionEmployerSociety
![Page 21: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/21.jpg)
Types of Costs Direct Medical Costs
Direct Non-Medical Costs
Indirect Costs
Intangible Costs
![Page 22: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/22.jpg)
Direct Medical Costs What is paid for specific health care
services, such as physician services, hospitalization, and pharmaceuticals
EX: Physical therapy, drugs to tx side effects, costs of clinic visits
![Page 23: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/23.jpg)
Direct Non-Medical Costs Costs necessary to enable patients to
receive medical care
EX: Transportation to and from visits, lodging, baby-sitters (special diet)
![Page 24: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/24.jpg)
Indirect Costs Measure of the patient’s lost productivity
plus the lost productivity of all unpaid caregivers
EX: Time off from work, less productive days, spouses time off from work.
![Page 25: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/25.jpg)
25
Intangible Costs Reflect the patient’s level of pain and
suffering. These are the hardest to measure.
Anxiety, chronic pain, loss of functioning
![Page 26: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/26.jpg)
Examples A daughter takes a week off from work to attend to her ill
father
Inpatient charge of R$268 per day for acute care
Fatigue from chemotherapy
Taxi fare to emergency department
Ambulance service to emergency department
![Page 27: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/27.jpg)
Examples A daughter takes a week off from work to attend to her ill father
INDIRECT COSTS (productivity) Inpatient charge of R$268 per day for acute care
DIRECT MEDICAL COSTS Fatigue from chemotherapy
INTANGIBLE COSTS Taxi fare to emergency department
DIRECT NON-MEDICAL COSTS Ambulance service to emergency department
DIRECT MEDICAL COSTS
![Page 28: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/28.jpg)
Example – Types of Costs for Schizophrenia Direct Medical
Medications Outpatient/
professional services Inpatient services Long-term care
Direct Non-Medical Law enforcement Shelters
Indirect Unemployment Reduced productivity
at work Premature mortality
(suicide) Caregiver
![Page 29: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/29.jpg)
Incremental Costs Average costs = total cost / total units Incremental = Change in total cost /
change in units
Example: Drug A is R$500 per patient and is 95% effective while Drug B is R$750 per patient and 97% effective
![Page 30: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/30.jpg)
Incremental Calculation
(R$750 – R$500) / (0.97 – 0.95) =
R$12,500 per extra cure
![Page 31: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/31.jpg)
Adjusting for Time DifferencesTwo different concepts Inflation
If data collected over more than one yearPrices may be adjusted to uniform price
Time Preference If program or therapy extends more than one
year, “discounting” is appropriateUsed even if inflation rate is zero
![Page 32: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/32.jpg)
Adjustment for Inflation
Can count number of services/ resources used and multiply by standard costs at one point in time
OR
Use inflation rate for past years times cost from past years
![Page 33: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/33.jpg)
Adjustment for Inflation
Medical Resources To Treat Mild Infection
Cost Estimate for Resource
Year of Cost Estimate
Cost Adjusted to 2007 R
Office Visits R$115.00 2005 R$128.00a
Lab to Culture Organism
R$50.00
2006
R$53.55b
Antibiotic Medication
R$28.84
2007
R$28.84
TOTAL R$210.39 a: Brazilian CPI for 2005 to 2007 = 11.3% b: Brazilian CPI for 2006 to 2007 = 7.1 %
Example of Standardization: Using Consumer Price Index (CPI) - Brazil
![Page 34: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/34.jpg)
Discounting A time preference is associated with money Current and future costs are not valued the
same If the treatment costs (and outcomes*)
extend for more than one year, discounting should be conducted to account for this difference.
![Page 35: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/35.jpg)
Present Value (PV) Formula PV = Sum of [FC / (1+r)n] for each year in
future
FC = Future Costs (or benefits) n = number of years r = discount rate per year
![Page 36: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/36.jpg)
Discounting Example
Year Costs are Incurred
Estimated Costs w/o Discounting
Calculation Present Value (PV)
Year 1 R$ 5,000 R$ 5,000 /1.05 R$ 4,762 Year 2 R$ 3,000 R$ 3,000 / (1.05)2 R$ 2,721 Year 3 R$ 4,000 R$ 4,000 / (1.05)3 R$ 3,455 Total Net Present Value (NPV)
R$ 12,000 R$ 10,938
Using a 5% discount rate
![Page 37: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/37.jpg)
Sensitivity Analysis For any costs “estimates” that are uncertain,
a sensitivity or “what if” analysis should be conducted.
How do we know the discount rate is 5%?. Vary the rate from 0% to 10% and see if decision of “least costly” alternative still holds.
Or vary cost of hospitalizations by area
![Page 38: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/38.jpg)
Costs - Summary When determining costs:
What is the perspective?
Are relevant/realistic costs included?
Is discounting or cost adjustment appropriate?
Is a sensitivity analysis conducted for uncertain values?
![Page 39: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/39.jpg)
Types of Pharmacoeconomic StudiesCost-Minimization
Analysis (CMA)
Costs = Monetary units
Outcomes = The same
Cost-Effectiveness Analysis (CEA)
Costs = Monetary units
Outcomes = Natural/clinical units
Cost-Utility
Analysis (CUA)
Costs = Monetary units
Outcomes = Adjusted by quality/utility (e.g., QALY, DALY)
Cost-Benefit Analysis (CBA)
Costs = Monetary units
Outcomes = Monetary units
![Page 40: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/40.jpg)
Cost-Minimization Analysis (CMA) Costs are measured in monetary units
Outcomes are assumed to be equivalent
Examples: compare generics or home vs. outpatient services.
![Page 41: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/41.jpg)
CMA Research Example
Cost-minimization analysis of erlotinib in the second-line treatment of non-cell lung cancer: A Brazilian perspective
Doral Stephani S; Giorgio Saggia M; Vicino dos Santos EA.
Journal of Medical Economics 2008; Vol. (3), p. 383-96.
![Page 42: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/42.jpg)
Example CMA
Budget impact of erlotinib versus docetaxol or pemetrexed as second-line treatment for NSCLC
Perspective = Private healthcare payer Costs = Panel assessed local costs Outcomes = from clinical trial that
assessed progression-free survival
![Page 43: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/43.jpg)
Example CMA
Erlotinib was cost saving ($R26,825) compared to established chemotherapy (R$40,217 and R$78,911)
Sensitivity analysis showed robustness
![Page 44: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/44.jpg)
Cost-Effectiveness Analysis (CEA) Advantage: Do not have to place a
dollar value on clinical outcomes Disadvantage: Can only compare
options with the same type of outcome, and only one outcome at a time can be measured.
![Page 45: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/45.jpg)
Cost-Effectiveness GridCost Outcome
Lower cost Same Cost Higher Cost
Less effective A B C
Same effectiveness
D E F
More effective
G H I
![Page 46: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/46.jpg)
Cost-Effectiveness GridCost Outcome
Lower cost Same Cost Higher Cost
Less effective A B C
Same effectiveness
D E F
More effective
G H I
![Page 47: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/47.jpg)
Cost-Effectiveness Plane
Cost Differences (+)
Cost Differences (-)
Effect Differences
Quadrant IV Dominated
Quadrant I Trade-off
Effect Differences
(-) Quadrant III
Trade-off
Quadrant II Dominant
(+)
![Page 48: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/48.jpg)
Cost-Effectiveness Plane
Cost Differences (+)
Cost Differences (-)
Effect Differences
Quadrant IV Dominated
Quadrant I Trade-off
Effect Differences
(-) Quadrant III
Trade-off
Quadrant II Dominant
(+)
![Page 49: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/49.jpg)
Examples of Ways to Present Cost and Effectiveness Results
Method Drug A Drug B Drug C
Costs
R$ 600 per year
Costs
R$ 210 per year
Costs
R$ 530 per year
Method 1
Cost-Consequence
Analysis (CCA)
Outcomes
GI SFDs = 130
% Healed = 50%
Outcomes
GI SFDs = 200 days
% Healed = 70 %
Outcomes
GI SFDs = 250 days
% Healed = 80 %
GI SFDs = gastro-intestinal symptom-free days
![Page 50: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/50.jpg)
Examples of Ways to Present Cost and Effectiveness Results
Method Drug A Drug B Drug C
R$ 600 / 130 =
R$ 4.61 per SFD
R$ 210 / 200 =
R$ 1.05 per SFD
R$ 530 / 250 =
R$ 2.12 per SFD
Method 2
Average Cost
Effectiveness Ratios R$ 600 / 0.5 = R$ 1,200 per cure
R$ 210 / 0.7 = R$ 300 per cure
R$ 530 / 0.8 = R$ 662 per cure
GI SFDs = gastro-intestinal symptom-free days
![Page 51: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/51.jpg)
Examples of Ways to Present Cost and Effectiveness Results
Method 3
Incremental Cost- Effectiveness Ratios
B compared to A = dominant for both SFDs and % healed;
C compared to A = dominant for both SFDs and % healed;
C compared to B = R$ 530 – R$ 210 / 250 – 200 SFDs = R$ 6.40 per extra SFD
C compared to B = R$ 530 – R$ 210 / .8 – 0.7
= R$ 3,200 per extra healed ulcer
GI SFDs = gastro-intestinal symptom-free days
![Page 52: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/52.jpg)
Cost-Utility Analysis(Some consider this a type of CEA) Costs measured in dollars
Consequences measured in preference-based measures, such as QALYs/DALYs
Incorporates mortality and morbidity (quality and quantity of life)
![Page 53: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/53.jpg)
Steps in Utility Analysis Describe the health state Choose the instrument Administer the instrument Calculate utility Calculate QALYs
![Page 54: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/54.jpg)
Describe the Health State Example: You often feel tired and sluggish. A
piece of tubing has been inserted into a vein in your arm or leg. This may restrict your movement. There is no severe pain, but rather chronic discomfort. You must go to the hospital 2-3 times per wk (8 hours per visit). You must follow a strict diet (low salt, little meat, small amount of fluid, no alcohol). Many people become depressed because of the nuisances and restrictions, some feel they are being kept alive by a machine.
![Page 55: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/55.jpg)
Choose the InstrumentTHREE COMMON METHODS
Rating Scales
Time trade-off (TTO)
Standard Gamble (SG)
![Page 56: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/56.jpg)
Rating Scale Endpoints = Dead / Healthy Other health states are explained and
subjects are asked to “rate “ them between the two endpoints
May look like a thermometer Can compare many health state options
and ask raters to place them on one scale
![Page 57: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/57.jpg)
Rating Scale
Perfect Health
Death
Disease state
100
0
58
![Page 58: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/58.jpg)
Time Trade-off Subjects are offered two alternatives:
State i for time t, followed by death, orHealthy time x (less than t) followed by death
Time x is varied until the subject is indifferent between the two alternatives
![Page 59: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/59.jpg)
Alternative 2
Alternative 1
x t
1.0
0
i
Time Trade-off
![Page 60: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/60.jpg)
Standard Gamble Subject is offered two alternatives:
Alternative 1 is a treatment with 2 possible alternatives; pt. lives healthy life for x years or dies immediately
Alternative 2 is the certain outcome of chronic state i for the rest of their natural life
![Page 61: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/61.jpg)
Standard Gamble
p
1-pAlternative 1
Alternative 2
i
dead
healthy
![Page 62: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/62.jpg)
Comparing the 3 Methods Rating Scale easiest but time not incorporated
as easily, must transform to QALYs TTO conceptually easier than SG SG and TTO give higher values than most using
rating scales TTO sometimes lower than SG Some consider SG to be “gold standard” Much research left to answer “which is best”
![Page 63: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/63.jpg)
Administer the Instrument - to whom? The general public
societal perspectivehard to describe to general public
People with the disease if comparing people with the same diseasemay be biased
Health Professionals / Disease Expertsdo not have to explain or describemay be biased
![Page 64: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/64.jpg)
Calculate Utilities Selected utilities from rating scale
1.0 Completely healthy .84 Kidney transplant .58 Hosp. dialysis (pts) .56 Hosp dialysis (public) .33 Hosp confinement0.0 Dead<0 ?
![Page 65: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/65.jpg)
Calculate QALYs For example if dialysis extends a life 10
years at .58 on rating scale = 5.8 QALYs If Option A cost R$5000 and extends life
for 6 years at a quality of .8 and Option B costs R$4000 and extends life for 10 years at a quality of .3, according to CUA which would be preferred?
![Page 66: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/66.jpg)
Based on CEA (no adjustment for quality) which option would you pick?
Option Cost YLS QALYS
A R$5000 6 years 0.8*6 =
4.8 QALYS
B R$4000 10 years 0.3* 10LYS
3.0 QALYS
1. Option A
2. Option B
3. Need ICER
![Page 67: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/67.jpg)
Based on CEA (no adjustment for quality) which option would you pick?
Option Cost YLS QALYS
A R$5000 6 years 0.8*6 =
4.8 QALYS
B R$4000 10 years 0.3* 10LYS
3.0 QALYS
1. Option A
2. Option B
3. Need ICER
![Page 68: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/68.jpg)
Based on CUA (QALYS) Which option would you pick?
Option Cost YLS QALYS
A R$5000 6 years 0.8*6 =
4.8 QALYS
B R$4000 10 years 0.3* 10LYS
3.0 QALYS
1. Option A
2. Option B
3. Need ICER
![Page 69: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/69.jpg)
Based on CUA (QALYS) Which option would you pick?
Option Cost YLS QALYS
A R$5000 6 years 0.8*6 =
4.8 QALYS
B R$4000 10 years 0.3* 10LYS
3.0 QALYS
1. Option A
2. Option B
3. Need ICER
![Page 70: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/70.jpg)
DALYS
DALYs = Disability Adjusted Life Years Similar to QALYs DALYs = The sum of years of potential life
lost due to premature mortality and the years of productive life lost due to disability.
QALYs = Years of healthy life (sum of quality * years)
![Page 71: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/71.jpg)
Advantages of CUA Includes patients’ preferences
Provides a single measure to incorporate morbidity and mortality
Allows comparisons across different options
![Page 72: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/72.jpg)
Disadvantages of CUA Time consuming Results vary depending on who assesses the
conditions and by what instrument is used Should you discount utilities? Unanswered questions - Is a 20 QALY gain for
one person = a 1 QALY gain for 20 people?
How much is a QALY/DALY worth?
![Page 73: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/73.jpg)
Cost-Benefit Analysis (CBA)
Costs measured in monetary units
Outcomes measured in monetary units
Calculate Benefit-to-Cost (B:C) ratio
![Page 74: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/74.jpg)
Cost-Benefit Analysis (CBA)
Advantage = can summarize benefits from many sources into one number (money) and compare vastly different options
Disadvantage = difficult to place monetary value on health outcomes
![Page 75: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/75.jpg)
Costs ($) Benefits ($)
Direct Benefits $ Indirect Benefits $ Intangible Benefits $
Productivity Patient PreferencesPain
Suffering
Human Capital (HC)
Willingness-to-pay (WTP) WTP
Medical Non-medical
Medical Non-medical
![Page 76: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/76.jpg)
Human Capital
Value of health benefits=the economic productivity they permitCost of disease=lost productivity
Cost of a sick day=how much you earn that day
![Page 77: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/77.jpg)
Human Capital
Use discounted values of expected earningsCensus estimates (age, gender, education)Gather data from individualsLabor income is estimated as before-tax income
Non-labor income is excluded (interest, etc.)
Use market values value for non-market activities (unpaid household work, child care, etc.)
![Page 78: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/78.jpg)
Human Capital
Problems Biased against specific groups
Age, gender, education
Earnings may not equal the value of outputs Professional athlete versus teacher
Does not include values for pain and suffering if the disease state or condition does not impact productivity
E.g., Menopause, Impotence vs. Diabetes, Cancer
![Page 79: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/79.jpg)
Willingness-to-Pay
Valuation of goods/services are easier for marketed vs. non-marketed goods/services Health care vs. coffee or pair of jeans
Valuation of goods/services are based on: Need
e.g., health care (pain/suffering, productivity, etc.)
Resources Preference
![Page 80: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/80.jpg)
Willingness-to-Pay
Determines how much people are willing to pay to reduce the chance of an adverse health outcome.Example: If a person was willing to pay
R$20 for a ½ hour visit with a pharmacist to improve their diabetes condition, then the imputed benefit/person/visit would be R$20.
![Page 81: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/81.jpg)
Willingness-to-Pay Problems
What people say vs. what they will really pay
Inherent biases of surveys (e.g., starting point bias, income bias)
Can the average person answer questions
![Page 82: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/82.jpg)
HC vs. WTP
Easier to measure
Only considers productivity (in terms of earnings)
Biases against specific groups
More difficult to measure
Captures productivity, patient preferences (intangibles)
Biases may not give accurate responses
HC WTP
![Page 83: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/83.jpg)
CBA Research Example
Costs and Benefits of Influenza Vaccination and Work Productivity in a Columbian Company from the Employer’s Perspective
Morales A, et al. Value in Health, Vol 7, No 4, 2004, p. 433-
441.
![Page 84: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/84.jpg)
CBA Example
Columbian bank employees volunteered to be in a prospective study involving vaccination versus no vaccination for influenza – 8 monthly questionnaires
CBA to determine if employer would save money offering vaccination to employees (therefore perspective = employer (title)
![Page 85: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/85.jpg)
CBA Example
Fever of at least 2 days with at least one symptomatioc symptom (fevers, chills, myalgia) and at least one respiratory problem (rhinorrhea, sore throat, cough, hoarseness) = Influenza-like illness (ILI)
![Page 86: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/86.jpg)
CBA Example
Input costsDirect = vaccine and materials, nurse Indirect = time lost by employee when getting
vaccinated (20 min) and if any days lost due to effects from vaccine
Outcome costs (diff vacc vs. no vacc) Indirect = sick leave and reduced efficiency at
work due to ILI
![Page 87: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/87.jpg)
CBA Example
Vaccinated = 14.6% ILI Non-vaccinated = 39.4% ILI Employer saved $6 to $26 US per
employee vaccinated (depending on assumed efficiency at work with ILI – range 70% to 30%)
![Page 88: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/88.jpg)
Part IV - Assessment of Pharmacoeconomic Studies
1. Is the title appropriate?
2. Is the question (objective) clear?
3. Are the alternatives appropriate?
![Page 89: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/89.jpg)
Assessment4. Are alternatives described in detail?
5. Is the perspective addressed?
6. Is the type of study stated? What type was it?
![Page 90: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/90.jpg)
Assessment7. Are relevant and realistic costs included/
justification for those not included?
8. Are relevant consequences/outcomes included/ justification for those not included?
9. Was adjustment or discounting needed/conducted?
![Page 91: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/91.jpg)
Assessment10. Are assumptions stated/reasonable?
11. Was a sensitivity analysis conducted for important estimates/assumptions?
12. Were major limitations addressed?
![Page 92: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/92.jpg)
13. Were appropriate generalizations made? Were extrapolations beyond population appropriate?
14. Is an unbiased, impartial attitude portrayed? Was an unbiased summary of the results presented?
Assessment
![Page 93: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/93.jpg)
Part V - Evaluate Example 1
Economic Impact of a Rotavirus Vaccine in Brazil
Journal of Health Population Nutrition, 2008, Vol 26 (4), p 388-396.
![Page 94: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/94.jpg)
Outline
Day 2Part VI – Decision AnalysisPart VII – Markov ModelingPart VIII – Evaluation ExamplePart IX – Future Issues
![Page 95: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/95.jpg)
Part VI - Decision Analysis
A systematic, quantitative approach for assessing the relative value of one or more decision options.
![Page 96: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/96.jpg)
Steps in Decision Analysis
Identify the specific decisionWhat is the perspective?
What are the competing options?
Over what period of time?
![Page 97: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/97.jpg)
Steps in Decision Analysis
Draw the structure over timeBoxes represent choice nodes
(Drug A vs. Drug B)Circles represent chance nodes
(S.E. or no S.E.)Triangles represent termination nodes
(live vs. die)
![Page 98: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/98.jpg)
Steps in Decision Analysis
Assess the probabilities
Use past literature, experts, judges, panels
Use reasonable ranges for uncertain probabilities
![Page 99: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/99.jpg)
Steps in Decision Analysis
Determine the value of each outcome
Options must have the same type of outcome ( $ vs. $ or QALY vs. QALY)
Can look at costs and effectiveness in the same model
![Page 100: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/100.jpg)
Steps in Decision Analysis Conduct a sensitivity analysis
Choose those values or probabilities that are most uncertain or those where a small difference has a big impact on the results
Use reasonable ranges
Calculate threshold values
![Page 101: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/101.jpg)
Example
From an article by Alan Baskt, Pharm.D.
“Pharmacoeconomics and the formulary decision-making process” in Hospital Formulary, Vol 30, Jan 1995, p.42-50.
![Page 102: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/102.jpg)
Example - ID Decision Background
DVT prophylaxisNewer agent Enoxaparin (Lovenox)No coagulation monitoring requiredLower DVT rate than heparin26 times more expensive than heparin
![Page 103: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/103.jpg)
Example - ID Decision Perspective
Societal Options
enoxaparin fixed-dose heparin low dose warfarin
Time frameabout 1 month
![Page 104: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/104.jpg)
Example - Draw Structure
![Page 105: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/105.jpg)
Example - Assess Probabilities
Incidence Warfarin Enoxaparin Heparin
Proximal DVT
5 % 2% 4.8%
Distal DVT
19% 2% 5.3%
Pulmonary Embolism
2.7% 0.1% 1.9%
Major Bleeding
1.3-3.6% 4.1% 6.2%
Minor Bleeding
6.9% 8.2% 5.7%
![Page 106: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/106.jpg)
Example - Determine ValuesCosts Warfarin Enoxaparin Heparin
Drug 0.14 159.88 6.10
PT test x 7 d 8.68 0 0
PTT test x 7 d 8.68 0 8.68
3 home visits 60.00 0 0
CCF nurse 20.87 0 0
PT and APTT x 3 visits
7.44 0 0
Outpt. Rx 12.30 0 0
TOTAL $118.11 $159.88 $14.78
![Page 107: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/107.jpg)
Example - Determine Values
Complication Abbrev. Cost
Proximal DVT Comp1 $1,394
Distal DVT Comp2 $ 860
P. Embolism Comp3 $6,510
Major Bleed Comp4 $2,791
Minor Bleed Comp5 $ 189
![Page 108: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/108.jpg)
![Page 109: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/109.jpg)
![Page 110: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/110.jpg)
![Page 111: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/111.jpg)
![Page 112: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/112.jpg)
![Page 113: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/113.jpg)
Part VII - Markov Modeling
Real health consequences more complex May need to look at long-term consequences
over multiple years Patients may “transition” from one health state to
another over time Basic decision trees get too complex after a few
cycles Researchers use Markov Modeling to assist with
more complex and chronic disease states
![Page 114: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/114.jpg)
![Page 115: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/115.jpg)
![Page 116: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/116.jpg)
Part VIII Evaluate Example 2
Cost-effectiveness Analysis of Cervical Cancer Vaccine in Five Latin American Countries
Colantonio L, et al. Vaccine, Volume 27, 2009, p. 5519-5529
![Page 117: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/117.jpg)
Part IX - Issues Perspective - Whose costs? Appropriate comparators Efficacy vs. Effectiveness
CriteriaLength of follow-upSwitching
OutcomesAccuracy of measurementMultiple measures
![Page 118: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/118.jpg)
Issues Barriers
Does not include budget impactLack of expertise in economic
evaluationsDecision-makers mistrust resultsSeen as “rationing” – may not want to
acknowledge resources are limited or that trade-offs are necessary
![Page 119: Introduction to Pharmacoeconomics September 15 -16, 2009 Karen L. Rascati, PhD, Professor The University of Texas College of Pharmacy Austin, Texas, USA.](https://reader030.fdocuments.net/reader030/viewer/2022032707/56649e445503460f94b37e91/html5/thumbnails/119.jpg)
For More Information (in addition to my book, of course)… Methods for the Economic Evaluation of Health
Care Programmes, 3rd ed. Drummond, Sculpher, Torrance, O’Brien and Stoddart, 2005
Health Care Cost, Quality, and Outcomes: ISPOR Book of Terms, Berger et al, 2003 – available soon in Portuguese.
International Society for Pharmacoeconomics and Outcomes Research http://www.ispor.org